摘要
目的观察rhEPO治疗急性脑梗死的疗效。方法选取急性脑梗死患者40例,随机分为rhEPO组和对照组,每组20例。其中rhEPO组于入院后在常规治疗基础上开始使用rhEPO,采用3000IU/次,皮下注射,2次/周,疗程2周。对照组不给予rhEPO,仅给予常规治疗。对所有病例均于治疗开始及治疗14d后进行NIHSS评分、Barthel指数(BI)评分和Fugl-Meyer(FMA)总分评定。结果治疗前两组NIHSS评分、BI及FMA总分评分相近,差异无统计学意义(P>0.05)。治疗14d后再次评定两组BI及FMA总分评分均有所提高及NIHSS评分明显降低,但rhEPO组患者提高幅度更大,经t检验两组差异有高度统计学意义(P<0.01)。总有效率rhEPO组为90.0%,对照组为80.0%,两组差异有高度统计学意义(P<0.01)。结论联合rhEPO治疗急性脑梗死比单纯常规治疗疗效好,rhEPO有望为脑梗死的临床治疗提供新的治疗手段。
Objective To observe the curative effect of rhEPO on the sufferers with acute cerebral infarction.Methods 40 sufferers with acute cerebral infarction were divided randomly into rhEPO group and control group with 20 cases in each group.The rhEPO group were given, besides conventional treatment, rhEPO treatment with the subcutaneous injection dosage of 3 000 IU/ time, twice a week for 2 weeks.The control group were just given conventional treatment without rhEPO.AI1 sufferers were assessed with the National Institutes of Health Stroke Seale（NIHSS）, the Barthel Index（BI）and the Fugl-Meyer motor fimction scale（FMA）before the treatment and 14 days after treatment.Results Before the treatment, the NIHSS scores, BI scores and FMA scores were similar between two groups, and the differences were not of statistical significance（P〉 0.05）.14 days after the treatment ,the BI scores and FMA scores of the two groups in- creased and the NIHSS scores clearly decreased, while the rhEPO group increased much more, and the differences of the two groups were of high statistical significance after T-test （P〈 0.01）.The total effective rate of the rhEPO group was 90.0%, while the total effec- tive rate of the control group was 80.0%.The differences of the two groups were of high statistical significance（P 〈 0.01）.Conclusion The clinical curative effect of rhEPO combined with conventional treatment on acute cerebral infarction is better than that of pure con- ventional treatment.So rhEPO has provided a new way for clinically treating acute cerebral infarction.
出处
《中国疗养医学》
2013年第4期298-300,共3页
Chinese Journal of Convalescent Medicine
基金
973国家重点基础研究发展计划资助项目(2004CB720302)
